Objective-Daily vitamin D supplementation is often inadequate in treating vitamin D deficiency due to poor compliance. A single, large dose of vitamin D given at timed intervals may be an alternative strategy.
INTRODUCTION
Vitamin D insufficiency is linked not only to bone disease (1,2) but also to several nonskeletal conditions, including type 2 diabetes mellitus (DM) (3), cardiovascular disease (4-7), chronic lung disease (8) (9) (10) (11) , tuberculosis (TB) (12) (13) (14) , and upper respiratory infections (15, 16) . Vitamin D status is determined by serum 25-hydroxyvitamin D (25[OH]D), the major circulating form of vitamin D (17) . Controversy exists as to what serum concentration of 25(OH)D is sufficient; whereas The Endocrine Society Clinical Practice Guidelines on vitamin D have defined sufficiency as >30 ng/mL (18) , the Institute of Medicine (IOM) suggests there is no consistent benefit associated with serum 25(OH)D concentrations >20 ng/mL (19, 20) .
Correction of vitamin D insufficiency is commonly achieved using oral vitamin D supplements. The Endocrine Society guidelines suggest that daily intake of 1,500 to 2,000 international units (IU) of vitamin D is necessary to achieve serum 25(OH)D concentrations consistently >30 ng/mL in adults (18) . However, adherence to daily doses has been reported to be low in several large clinical trials (1) . Poor adherence has been associated with difficulty swallowing combined vitamin D/calcium tablets, gastrointestinal (GI) side-effects (21) , the number of concurrent treatments a patient is receiving, and the patient's attitude towards vitamin D supplementation (22) . Vitamin D given as a large bolus dose has demonstrated higher adherence rates compared with daily and monthly dosing regimens, and has the potential to yield sustained improvements in serum 25(OH)D and parathyroid hormone (PTH) concentrations (23) . The sustained effect of high-dose vitamin D may be attributed to its long half-life. Upon ingestion, vitamin D is either converted to 25(OH)D or redistributed into fat, from which it is slowly released over time. By this mechanism, IshShalom et al (24) suggested that daily, weekly, and monthly vitamin D dosing will result in the same circulating concentrations of 25(OH)D over an equivalent period of time. The purpose of this systematic review was to investigate the effects of single, large, bolus doses of vitamin D on serum 25(OH)D concentrations, PTH suppression, and other health outcomes in adults.
METHODS
We searched the terms "high dose vitamin D," "single dose vitamin D," "bolus vitamin D," or "annual dose vitamin D" in PubMed for articles published through September 1, 2012. Limits were preset to manuscripts published in the English language. Titles and abstracts were reviewed. Review articles, cross-sectional studies, non-human studies, and responses to other articles were excluded. Manuscripts were also excluded if the studies: (1) did not use oral cholecalciferol or ergocalciferol, (2) used analog compounds of vitamin D (i.e., calcitriol, doxercalciferol, paricalcitol), (3) study participants were under age 18 years, (4) the study administered doses <100,000 IU (2.5 mg), or (5) vitamin D was given more than once within a year. Manuscripts that could not be excluded by review of title and abstract were examined in their entirety. We also searched the Cochrane databases using the same criteria. Two independent reviewers (J.A., M.K.) identified manuscripts with these criteria, and a third reviewer (V.T.) determined manuscript eligibility when there were disagreements.
Outcomes of interest included: (1) serum/plasma 25(OH)D, (2) serum/plasma PTH, (3) differences between vitamin D 2 and D 3 , and (4) adverse effects.
PubMed Search Results
There were 2,243 manuscripts identified from the specified search terms (Fig. 1) , and 42 were deemed potentially eligible after applying exclusion criteria to the title and abstract. Following review of these manuscripts, 12 studies were subsequently excluded by criteria not included in the title and abstract. No papers were added from the references of selected manuscripts or the Cochrane databases. A total of 30 studies were included in this review. Of the 30 manuscripts evaluated, three (25) (26) (27) provided secondary analyses of data that was published in earlier studies that were also included in this paper (28) (29) (30) .
RESULTS

Study Design
The 30 studies that met eligibility criteria of this paper were published after 1990 and evaluated adult populations receiving single, oral vitamin D doses >100,000 IU. Elderly populations were sampled in 14 studies (26, 27, (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) , and vitamin D-deficient adults were observed in 2 studies (41, 42) . Five studies evaluated cardiovascular risk factors (DM, insulin resistance, peripheral artery disease [PAD] , and stroke history) (3, (43) (44) (45) (46) . Two studies evaluated populations with autoimmune and inflammatory conditions (primary dysmenorrhea and rheumatologic patients) (47, 48) . Seven studies looked at populations with infectious or acquired conditions (alcoholic liver cirrhosis [49] , cystic fibrosis [CF] [25, 28] , TB [50, 51] , intensive care unit [ICU] placement [52] , and pregnancy [53] ). Table 1 provided additional analysis of previously published studies that were already included in the table. The remaining 6 studies (32, 37, 42, 46, 47, 49) are discussed below when relevant to adverse events or secondary measures.
Vitamin D on Serum/Plasma 25(OH)D and PTH Concentrations
Oral doses of vitamin D 2 and D 3 (100,000 to 600,000 IU) significantly increased serum 25(OH)D concentrations from baseline in all reviewed studies. The greatest increases in serum 25(OH)D consistently occurred between days 1 and 30 (Fig. 2) ; peak levels were measured at 3 days (34) and 7 days (25, 40, 49) following dosing, although concentrations >30 ng/mL were noted as soon as 1 day following 600,000 IU of D 3 (34) and 540,000 IU of D 3 (52) . Improvement in vitamin D status was associated with lowering of PTH concentration in a majority of the studies (30, 31, (34) (35) (36) 38, 39, 41, 52, 53) ; significant decreases (P<.001) were noted as soon as day 3 in studies using 600,000 IU of vitamin D 3 (34) and remained significantly decreased for as long as 12 months (following 600,000 IU of vitamin D 3 ) (36). However, lower single doses of vitamin D in the range of 100,000 to 500,000 IU did not significantly lower PTH concentrations in several studies (3, 25, 28, 29, 40, (43) (44) (45) .
Data regarding PTH and 25(OH)D modulation is stratified below by: vitamin D formulation (D 2 versus D 3 ), dose (100,000, 200,000 to 300,000, and >300,000 IU), and relative baseline 25(OH)D concentration (>20 ng/mL or <20 ng/mL).
Supplementation of 100,000 IU Vitamin D: Baseline Serum 25(OH)D <20 ng/mL
A 100,000 IU dose of vitamin D 3 in subjects with serum 25(OH)D <20 ng/mL failed to increase serum 25(OH)D concentrations to >30 ng/mL. However, serum 25(OH)D concentrations >20 ng/mL were sustained at: 4 weeks in patients with PAD (45), 5 weeks in healthy adults (27, 30) , and 8 (44) The dose of 100,000 IU of vitamin D was only associated with a significant lowering of PTH concentration in the study by Khaw et al (30) , which had a much larger sample size (N = 189) than the other studies that evaluated PTH lowering at this dose (N = 34 [44] , N = 61 [3] , N = 62 [45] ).
Supplementation of 100,000 IU Vitamin D: Baseline Serum 25(OH)D >20 ng/mL
Only Ilahi et al (40) In contrast, vitamin D 2 (ergocalciferol) in the dose range of 200,000 to 300,000 IU consistently failed to achieve 30 ng/mL concentrations of serum 25(OH) D (31, 33, 43, 53) , although concentrations >20 ng/mL occurred at: 8 weeks in vitamin D-deficient adults (31), 12 weeks in frail elderly (33) , and 16 weeks in stroke patients (43) . Yu et al (53) failed to achieve average 25(OH) D concentrations >20 ng/mL in a group of pregnant participants.
Vitamin D doses in the range of 200,000 to 300,000 IU were associated with significantly lower plasma PTH concentrations at 8 weeks in elderly adults (31, 35) and 24 weeks in vitamin D-deficient adults (41) . Only Witham et al (3) , who used a dose of 200,000 IU of vitamin D 3 , failed to observe a significant decrease in PTH over a 16-week study. Baseline 25(OH)D was relatively high (19.2 ± 8.4 ng/mL) in this population relative to other groups (range, 10.8 to 13.3 ± 9.9 ng/mL) (31, 35, 41) .
Three of four studies failed to show PTH lowering using 200,000 to 300,000 IU vitamin D 2 (31, 33, 43) ; only Yu et al (53) showed a significant decrease in PTH in pregnant women at delivery, following administration of 200,000 IU of vitamin D in the 27th week of pregnancy. This population exhibited a high prevalence (27%) of secondary hyperparathyroidism (53) .
Supplementation of 200,000-300,000 IU Vitamin D: Baseline Serum 25(OH)D >20 ng/mL
Two studies (28,48) achieved 25(OH)D concentrations >30 ng/mL at: 12 weeks following a dose of 300,000 IU vitamin D 3 in patients with rheumatologic conditions (48) and 1 week (not significant at 12 weeks) following a dose of 250,000 IU vitamin D 3 in patients with CF (28). Sakalli et al (38) did not show serum concentrations of 25(OH)D >30 ng/mL at 6 weeks in an elderly population; this study population only reached 27 ± 12 ng/mL. PTH suppression was inconsistent between studies. Grossman et al (28) showed no suppression in PTH concentration following a 250,000 IU dose of vitamin D 3 , whereas Sakalli et al (38) observed a significant decrease in PTH concentration at 6 weeks (82.7 ± 32.5 pg/mL to 50.8 ± 23.4 pg/mL). This study population had the highest PTH concentration at baseline of all studies evaluated.
Supplementation of >300,000 IU vitamin D: Baseline Serum 25(OH)D <20 ng/mL
Following a dose of 540,000 IU of vitamin D 3, mean serum 25(OH)D concentrations were >20 ng/mL by day 1 and peaked at 38.2 ± 16.5 ng/mL at 1 week in a population of ICU patients (52) . Similarly, a dose of 600,000 IU of vitamin D 3 raised serum 25(OH)D to >30 ng/mL by 12 weeks in elderly subjects (36) .
PTH concentrations were significantly lowered in both of the studies that evaluated PTH lowering in this subset of studies (36, 52) .
Supplementation of >300,000 IU vitamin D: Baseline Serum 25(OH)D >20 ng/mL
Vitamin D 3 doses >300,000 IU were similarly effective in patients with 25(OH)D concentrations >20 ng/mL; all 3 studies (29,34,39) observed mean concentrations >30 ng/mL at 4 weeks, though the results peaked at day 3 (reaching 67.1 ± 17.1 ng/mL from 21.7 ± 5.6 at baseline) in the study of Rossini et al (34) . Sanders et al (29) showed long-term efficacy of a 500,000 IU dose; the 25(OH)D concentration remained >30 ng/mL at 12 weeks and was significantly increased at 1 year in a cohort of women with osteoporosis. Bacon et al (39) did not sustain a mean 25(OH)D concentration >30 ng/mL at 12 weeks in a frail elderly population.
PTH concentrations were found to be significantly lower in both studies that evaluated this measure; Rossini et al (34) and Bacon et al (39) both showed significant suppression of PTH, which was significant 3 days following the dose (34) and was sustained at 4 weeks (34,39). Sanders et al (29) did not show a significant decrease in PTH. 
Adverse Effects
Few studies have documented complications following high-dose vitamin D supplementation. Three studies reported subjects with GI complaints, including an episode of vomiting following administration of 300,000 IU of vitamin D 3 in a vegetable-oil solution (41) and various GI complaints following ingestion of 300,000 IU of vitamin D 3 and 200,000 IU of vitamin D 2 in tablet form (n = 2 and n = 3, respectively) (35,53). Rossini et al (34) showed an increase in several bone turnover markers (collagen type 1 cross-linked Ntelopeptide and collagen type 1 cross-linked C-telopeptide) following 600,000 IU of vitamin D 3 . von Restorff (37) documented 2 participants with mild hypercalcemia (>10.76 mg/dL) that normalized by 6 months following a 300,000 IU dose of vitamin D 3 . Hypercalciuria immediately following ingestion of 300,000 IU of vitamin D 3 (38) and within 12 weeks of ingesting 600,000 IU of vitamin D 3 (36) , in addition to increased urine magnesium 3 days after 600,000 IU of vitamin D 3 (43) , has also been reported. The reports of hypercalciuria were not linked to any significant clinical complications (36, 38) . The clinical significance of increased urine magnesium was also unclear, as serum calcium and magnesium remained normal in these subjects (42) .
DISCUSSION
This systematic review demonstrated the consistent efficacy and safety of single, large, oral doses of vitamin D in adults. All studies evaluated report a significant increase in serum/ plasma 25(OH)D concentration relative to baseline, which tended to peak between days 7 and 30 ( (40), who reported a mean baseline 25(OH)D concentration of 27.1 ± 7. 7 ng/mL, were the only investigators who found that 100,000 IU of vitamin D 3 was sufficient to achieve 25(OH)D concentrations >30 ng/mL. Generally, doses of ≥200,000 IU of vitamin D 3 were required to sustain mean 25(OH)D concentrations >30 ng/mL (3, 28, 29, 31, (34) (35) (36) 39, 41, 48, 52) . Only Sakalli et al (38) narrowly failed to reach this benchmark, reaching 25(OH) D concentrations of 27 ± 12 ng/mL at 6 weeks.
The increases in 25(OH)D concentration observed occurred safely in a majority of individuals; no adverse effects were noted at doses <200,000 IU of vitamin D, and many studies found no adverse events at up to 500,000 IU of vitamin D 3 (26, 29, 31) and 540,000 IU of vitamin D 3 (52) . However, potentially detrimental changes in biochemical markers occurred in all studies evaluating a single dose of 600,000 IU of vitamin D 3 , indicating the need for greater discretion when administering single doses of >500,000 IU. Overall, whereas vitamin D 3 doses of ≥200,000 IU appear to be most effective in promoting vitamin D sufficiency, certain healthy, relatively vitamin D-sufficient populations, such as that in the study of Ilahi et al (40) , may benefit from smaller doses and may thus avoid the risk of adverse events with higher doses.
Vitamin D classically influences bone metabolism through its increase in GI tract absorption of calcium and subsequent lowering of PTH. Significant decreases in plasma PTH concentrations were observed in a majority of the studies evaluated, occurring as soon as day 3 in studies using 600,000 IU of vitamin D 3 (34) and remaining significantly decreased for as long as 12 months (following 600,000 IU of vitamin D 3 ) (36) . However, variability between results was evident. This inconsistency was likely due primarily to the dose of vitamin D administered. Vitamin D 3 doses <300,000 IU appeared generally insufficient at decreasing PTH concentrations, regardless of baseline 25(OH)D concentration (3, 28, 40, 44, 45) ; only 1 study (30) showed a significantly decreased PTH concentration using a 100,000 IU dose of vitamin D 3. Doses of ≥300,000 IU of vitamin D 3 showed more consistent PTH lowering; of studies evaluating PTH concentration, only that of Sanders et al (29) did not elicit a significant decrease in PTH concentration following a dose of 500,000 IU of vitamin D 3 in osteoporotic women. Overall, it appears that doses <300,000 IU may not provide an adequate amount of vitamin D to restore vitamin D status and lower plasma PTH concentrations in most populations. In addition, baseline serum 25(OH)D concentration does not appear to have an impact in decreasing PTH concentrations following a single, large dose of vitamin D >100,000 IU.
Lowered PTH concentrations in response to vitamin D supplementation have been associated with lower fracture risk (54, 55) . However, higher doses of vitamin D, in the range of 300,000 to 600,000 IU, may actually increase fracture risk (29, 34) , as seen in the study of Rossini et al (34) , which showed elevated bone turnover markers following a dose of 600,000 IU of vitamin D 3 . Rapidly increased calcitriol concentrations may have some osteoclastic activity (56) and may also inhibit osteoblast function in bone mineralization (57) . Additional studies are needed to determine the potential fracture risk posed by highdose vitamin D, particularly in patients at risk for fractures and osteoporotic changes. An optimal therapeutic dose of vitamin D must balance these potential negative impacts on bone mineralization.
In addition to the classical effects on bone outcomes, improving vitamin D status provides extraskeletal benefits for several populations at risk for vitamin D insufficiency. In patients with CF who were hospitalized for pulmonary exacerbation, a single dose of 250,000 IU of vitamin D 3 increased 1-year survival and the number of hospital-free days and decreased levels of inflammatory cytokines (25, 28) . A 100,000 IU dose of vitamin D 2 was found to decrease in vitro bacterial growth in a population with active TB and potentially prevent reactivation of latent TB infection (50). Lasco et al (47) suggested that a single 300,000 IU dose of vitamin D 3 reduced pain in women with dysmenorrhea. Vitamin D may also affect cardiovascular system factors, although this is inconclusive, as positive results were seen in some (3, 43, 44, 46) , but not all (27, 45) , of the studies reviewed.
The limitations of this review are based largely on the inconsistencies between study populations and vitamin doses, which prevent reliable inter-study comparisons, in addition to the lack of data from healthy, nonelderly, adult populations, which would allow the impact of vitamin D supplementation to be observed without concurrent disease processes. Furthermore, once-yearly doses of vitamin D are nonphysiologic; whereas large doses consistently show better efficacy than daily doses, there may be a more optimal intermittent dosing strategy not evaluated by this review. As discussed in Ilahi et al (40) , 100,000 IU of vitamin D 3 dosed every 2 to 3 months may provide optimal benefit in people with baseline 25(OH)D concentrations >20 ng/mL. Bacon et al (39) showed similar improvements in the sustainability of 25(OH)D concentrations in the long-term by adding monthly 50,000 IU vitamin D 3 doses following an initial 500,000 IU vitamin D 3 bolus. Such subannual dosing strategies may strike a balance between the convenience of once-yearly dosing and the poor compliance of daily dosing and thus serve to better maintain 25(OH)D concentrations in deficient populations.
CONCLUSION
In conclusion, a single vitamin D 3 dose of ≥100,000 IU offers a consistently efficient means of improving short-term vitamin D concentrations of >20 ng/mL, although vitamin D 3 doses of ≥300,000 IU are necessary to achieve 25(OH)D concentrations >30 ng/mL and lowering of plasma PTH concentrations. Although generally safe, bolus doses of >500,000 IU of vitamin D 3 must be used with caution due to the potential for increased fracture risks, altered biochemical markers, and issues with tolerability, such as GI upset. Flow diagram of studies identified for review. 
